text
stringlengths 81
4.38k
|
|---|
<s>[INST] Provide description for trial id: NCT03863457 [/INST] Patients with known or suspected primary or metastatic breast cancer with one lesion that is 1.5 cm in diameter or greater may be eligible for this study. Patients may participate in this study if they are at least 18 years of age. Up to 40 evaluable subjects will participate in a single imaging cohort. Patients will be stratified for analysis by breast cancer subtype with prioritization to recruit at least 10 estrogen-receptor-expressing (ER+) and 10 triple-negative breast cancers (TNBC).
This is an observational study; [18F]F-GLN PET/CT will not be used to direct treatment decisions. While patients and referring physicians will not be blinded to the [18F]F-GLN PET/CT results, treatment decisions are made by the treating physicians based upon clinical criteria.
[18F]F-GLN PET/CT imaging sessions will include an injection of [18F]F-GLN. Metabolism data will be collected. Pilot data will be collected to evaluate image quality and collect preliminary information on the uptake of [18F]F-GLN in breast cancer. Uptake measures will be compared to tumor markers of glutamine metabolism, when tissue is available. The safety of [18F]F-GLN will also be evaluated in all subjects. </s> |
<s>[INST] Provide title for trial id: NCT03863457 [/INST] [18F] F-GLN by PET/CT in Breast Cancer </s> |
<s>[INST] Provide the recruitment status for trial id: NCT03863457 [/INST] Recruiting </s> |
<s>[INST] Provide the medical condition for trial id: NCT03863457 [/INST] Breast Cancer </s> |
<s>Trial Id: Contrast Enhanced Spectral Mammography vs. MRI for Breast Cancer Screening Recruitment Status: Active, not recruiting Trail description: This research study is evaluating whether contrast enhanced mammography can be used as an alternative to breast Magnetic Resonance Imaging (MRI) for cancer screening Inclusion Criteria: Prospective Patient Recruitment
Women
Age > or equal to 30 years
Recommendation for breast biopsy has been made
Recommendation for biopsy will result from an imaging work-up originating with a screening exam (mammogram, tomosynthesis, ultrasound, or MRI) that was within 3 months of biopsy.
Reader Study Inclusion Criteria:
CESM and MRI exam performed within 3 months of one another.
CESM and breast MRI exams must be performed as part of imaging work-up based on a screening exam of any type (mammography, tomosynthesis, ultrasound, and MRI)
CESM studies will include at least four low energy and four recombined images (LCC, LMLO, RCC, RMLO).
MRI exams will include at least fluid sensitive sequence, multi-phase T1-weighted Exclusion Criteria: Prospective Patient Recruitment
Men
Women with implants
Participants who have a known allergy to contrast media.
Participants who have a known severe allergic response to one or more allergens, defined as anaphylaxis
Participants with poor asthma control using the National Heart, Lung, and Blood Institute guidelines as defined by:
Symptoms > 2 days per week Short-term beta agonist use > 2 days per week Nighttime awakenings > 2 times per month
Participants with Renal insufficiency or failure, as determined by GFR < 60 mL/min/1.73 m2 , performed for all patients within 24 hours of the imaging exams
Participants who are pregnant. Pregnant women are excluded from this study due to the radiation dose from the CT scan and its potential teratogenic effects on the fetus.
Participants who are breastfeeding are excluded because there is an unknown but potential risk for adverse events in nursing infants secondary to contrast administration in the mother.
Participants with the following underlying medical conditions: multiple myeloma, myasthenia gravis, dysproteinemias, severe cardiac disease, aortic stenosis, primary pulmonary hypertension, cardiac arrythmia, or severe cardiomyopathy. These underlying medical conditions may make the participant more likely to develop a contrast reaction. This is based on the ACR contrast manual version 10.3 and hospital policy.
Participants with a concurrent active illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, thyroid storm.
Participants with thyroid carcinoma or thyroid disease for whom systemic radioactive iodine therapy is part of planned diagnostic work-up or treatment within 2 months following the contrast mammogram study.
Participants with non-MR compatible objects or implants that would make MRI a contraindication.
Participants who have a pacemaker, pacer wires, implantable defibrillator, or implanted monitoring device.
Participants with intracranial clips, metal implants or external clips within 10 mm of the head.
Participants who have had a metal injury to the eye.
Reader Study Exclusion Criteria:
Imaging sets with implants.
Imaging sets in which a biopsy or surgical intervention was performed since the most recent screening exam, prior to acquisition of the study MRI or CESM.
Imaging sets in which a biopsy was recommended, but biopsy was not performed and 2 year imaging follow-up is not available </s> |
<s>[INST] Provide inclusion criteria for trial id: NCT03482557 [/INST] Prospective Patient Recruitment
Women
Age > or equal to 30 years
Recommendation for breast biopsy has been made
Recommendation for biopsy will result from an imaging work-up originating with a screening exam (mammogram, tomosynthesis, ultrasound, or MRI) that was within 3 months of biopsy.
Reader Study Inclusion Criteria:
CESM and MRI exam performed within 3 months of one another.
CESM and breast MRI exams must be performed as part of imaging work-up based on a screening exam of any type (mammography, tomosynthesis, ultrasound, and MRI)
CESM studies will include at least four low energy and four recombined images (LCC, LMLO, RCC, RMLO).
MRI exams will include at least fluid sensitive sequence, multi-phase T1-weighted </s> |
<s>[INST] Provide exclusion criteria for trial id: NCT03482557 [/INST] Prospective Patient Recruitment
Men
Women with implants
Participants who have a known allergy to contrast media.
Participants who have a known severe allergic response to one or more allergens, defined as anaphylaxis
Participants with poor asthma control using the National Heart, Lung, and Blood Institute guidelines as defined by:
Symptoms > 2 days per week Short-term beta agonist use > 2 days per week Nighttime awakenings > 2 times per month
Participants with Renal insufficiency or failure, as determined by GFR < 60 mL/min/1.73 m2 , performed for all patients within 24 hours of the imaging exams
Participants who are pregnant. Pregnant women are excluded from this study due to the radiation dose from the CT scan and its potential teratogenic effects on the fetus.
Participants who are breastfeeding are excluded because there is an unknown but potential risk for adverse events in nursing infants secondary to contrast administration in the mother.
Participants with the following underlying medical conditions: multiple myeloma, myasthenia gravis, dysproteinemias, severe cardiac disease, aortic stenosis, primary pulmonary hypertension, cardiac arrythmia, or severe cardiomyopathy. These underlying medical conditions may make the participant more likely to develop a contrast reaction. This is based on the ACR contrast manual version 10.3 and hospital policy.
Participants with a concurrent active illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, thyroid storm.
Participants with thyroid carcinoma or thyroid disease for whom systemic radioactive iodine therapy is part of planned diagnostic work-up or treatment within 2 months following the contrast mammogram study.
Participants with non-MR compatible objects or implants that would make MRI a contraindication.
Participants who have a pacemaker, pacer wires, implantable defibrillator, or implanted monitoring device.
Participants with intracranial clips, metal implants or external clips within 10 mm of the head.
Participants who have had a metal injury to the eye.
Reader Study Exclusion Criteria:
Imaging sets with implants.
Imaging sets in which a biopsy or surgical intervention was performed since the most recent screening exam, prior to acquisition of the study MRI or CESM.
Imaging sets in which a biopsy was recommended, but biopsy was not performed and 2 year imaging follow-up is not available </s> |
<s>[INST] Provide description for trial id: NCT03482557 [/INST] This research study is evaluating whether contrast enhanced mammography can be used as an alternative to breast Magnetic Resonance Imaging (MRI) for cancer screening </s> |
<s>[INST] Provide title for trial id: NCT03482557 [/INST] Contrast Enhanced Spectral Mammography vs. MRI for Breast Cancer Screening </s> |
<s>[INST] Provide the recruitment status for trial id: NCT03482557 [/INST] Active, not recruiting </s> |
<s>[INST] Provide the medical condition for trial id: NCT03482557 [/INST] Breast Cancer </s> |
<s>Trial Id: Study for the Knowledge of Risk Factors Associated With Breast Cancer in Women Recruitment Status: Completed Trail description: Breast cancer is the most frequent tumor in Western women. In Spain about 26,000 new breast cancers are diagnosed each year. This type of tumor is increasing worldwide with an increase in aggressive neoplasms in young women. There are some risk factors responsible for this global increase: lifestyle, diet and body weight especially in postmenopausal women.
Some cell mutations, especially in the BRCA1, BRCA2 and p53 genes, are associated with a very high risk of this type of cancer. Some authors have calculated the contribution of various modifiable risk factors to the global burden of breast cancer, and they concluded that 21% of all breast cancer deaths are attributable to alcohol consumption, overweight and obesity, and lack of physical activity. Nowadays, there aren't specific studies in the Community of Madrid designed to know the risk factors related to breast cancer.
For this reason, it is proposed to carry out an observational study that collects detailed information about dietary habits, genetic factors and life quality of a group of women with recent diagnosis in pre or post-surgical phase. Inclusion Criteria: Older women than 18 years old
Newly diagnosed patients with a breast tumor (Phase I, II or III). Being in one of the following cases:
Patient who has not yet received any treatment and the committee has decided that as a first treatment will receive chemo or radiotherapy.
Patient who has just undergone surgery and is waiting to start adjuvant treatment with chemo or radiotherapy.
Sign the informed consent. Exclusion Criteria: Patients with stage IV disease.
Associated Eating Disorders.
Patients with dementia, mental illness or decreased cognitive function.
Pregnant or lactating women. </s> |
<s>[INST] Provide inclusion criteria for trial id: NCT03918668 [/INST] Older women than 18 years old
Newly diagnosed patients with a breast tumor (Phase I, II or III). Being in one of the following cases:
Patient who has not yet received any treatment and the committee has decided that as a first treatment will receive chemo or radiotherapy.
Patient who has just undergone surgery and is waiting to start adjuvant treatment with chemo or radiotherapy.
Sign the informed consent. </s> |
<s>[INST] Provide exclusion criteria for trial id: NCT03918668 [/INST] Patients with stage IV disease.
Associated Eating Disorders.
Patients with dementia, mental illness or decreased cognitive function.
Pregnant or lactating women. </s> |
<s>[INST] Provide description for trial id: NCT03918668 [/INST] Breast cancer is the most frequent tumor in Western women. In Spain about 26,000 new breast cancers are diagnosed each year. This type of tumor is increasing worldwide with an increase in aggressive neoplasms in young women. There are some risk factors responsible for this global increase: lifestyle, diet and body weight especially in postmenopausal women.
Some cell mutations, especially in the BRCA1, BRCA2 and p53 genes, are associated with a very high risk of this type of cancer. Some authors have calculated the contribution of various modifiable risk factors to the global burden of breast cancer, and they concluded that 21% of all breast cancer deaths are attributable to alcohol consumption, overweight and obesity, and lack of physical activity. Nowadays, there aren't specific studies in the Community of Madrid designed to know the risk factors related to breast cancer.
For this reason, it is proposed to carry out an observational study that collects detailed information about dietary habits, genetic factors and life quality of a group of women with recent diagnosis in pre or post-surgical phase. </s> |
<s>[INST] Provide title for trial id: NCT03918668 [/INST] Study for the Knowledge of Risk Factors Associated With Breast Cancer in Women </s> |
<s>[INST] Provide the recruitment status for trial id: NCT03918668 [/INST] Completed </s> |
<s>[INST] Provide the medical condition for trial id: NCT03918668 [/INST] Breast Neoplasm Female, Nutrition Related Cancer, Habits, Diet, Cancer, Breast </s> |
<s>Trial Id: Breast MRI in Women With Known or Suspected Breast Cancer and in Healthy Participants Recruitment Status: Completed Trail description: RATIONALE: Diagnostic procedures, such as MRI, may help diagnose breast cancer. It may also help doctors predict a patient's response to treatment.
PURPOSE: This clinical trial is studying breast MRI in women with known or suspected breast cancer and in healthy participants. Inclusion Criteria: None Exclusion Criteria: None </s> |
<s>[INST] Provide inclusion criteria for trial id: NCT00474604 [/INST] None </s> |
<s>[INST] Provide exclusion criteria for trial id: NCT00474604 [/INST] None </s> |
<s>[INST] Provide description for trial id: NCT00474604 [/INST] RATIONALE: Diagnostic procedures, such as MRI, may help diagnose breast cancer. It may also help doctors predict a patient's response to treatment.
PURPOSE: This clinical trial is studying breast MRI in women with known or suspected breast cancer and in healthy participants. </s> |
<s>[INST] Provide title for trial id: NCT00474604 [/INST] Breast MRI in Women With Known or Suspected Breast Cancer and in Healthy Participants </s> |
<s>[INST] Provide the recruitment status for trial id: NCT00474604 [/INST] Completed </s> |
<s>[INST] Provide the medical condition for trial id: NCT00474604 [/INST] Breast Cancer </s> |
<s>Trial Id: Integrative Oncology Outcomes Study in Breast Cancer Recruitment Status: Completed Trail description: This NIH-NCCAM funded epidemiologic research is being conducted as an observational prospective case-control study of the use of Complementary and Alternative Medicine (CAM) and Integrated Oncology (IO) and their effects on breast cancer patients in community settings.
Hypothesis: IO services improve patients' quality of life and decrease cancer recurrence rates in breast cancer patients as compared to women with similar disease states and prognoses who do not receive IO care, and may or may not use CAM treatment on their own. Inclusion Criteria: None Exclusion Criteria: None </s> |
<s>[INST] Provide inclusion criteria for trial id: NCT01366248 [/INST] None </s> |
<s>[INST] Provide exclusion criteria for trial id: NCT01366248 [/INST] None </s> |
<s>[INST] Provide description for trial id: NCT01366248 [/INST] This NIH-NCCAM funded epidemiologic research is being conducted as an observational prospective case-control study of the use of Complementary and Alternative Medicine (CAM) and Integrated Oncology (IO) and their effects on breast cancer patients in community settings.
Hypothesis: IO services improve patients' quality of life and decrease cancer recurrence rates in breast cancer patients as compared to women with similar disease states and prognoses who do not receive IO care, and may or may not use CAM treatment on their own. </s> |
<s>[INST] Provide title for trial id: NCT01366248 [/INST] Integrative Oncology Outcomes Study in Breast Cancer </s> |
<s>[INST] Provide the recruitment status for trial id: NCT01366248 [/INST] Completed </s> |
<s>[INST] Provide the medical condition for trial id: NCT01366248 [/INST] Breast Cancer </s> |
<s>Trial Id: Characteristics and Treatment Trends of Young Breast Cancer in China Recruitment Status: Not yet recruiting Trail description: To describe the clinical characteristics, the diagnosis and treatment, the survival status and change trend of young breast cancer patients in China from 2000 to 2015, and to explore and discuss the main influencing factors. Inclusion Criteria: Young Breast cancer patients (≤35 years old) in China Exclusion Criteria: Breast cancer patients (>35 years old) in China </s> |
<s>[INST] Provide inclusion criteria for trial id: NCT05068115 [/INST] Young Breast cancer patients (≤35 years old) in China </s> |
<s>[INST] Provide exclusion criteria for trial id: NCT05068115 [/INST] Breast cancer patients (>35 years old) in China </s> |
<s>[INST] Provide description for trial id: NCT05068115 [/INST] To describe the clinical characteristics, the diagnosis and treatment, the survival status and change trend of young breast cancer patients in China from 2000 to 2015, and to explore and discuss the main influencing factors. </s> |
<s>[INST] Provide title for trial id: NCT05068115 [/INST] Characteristics and Treatment Trends of Young Breast Cancer in China </s> |
<s>[INST] Provide the recruitment status for trial id: NCT05068115 [/INST] Not yet recruiting </s> |
<s>[INST] Provide the medical condition for trial id: NCT05068115 [/INST] Breast Cancer </s> |
<s>Trial Id: Study on SBRT for Inoperable Lung and Liver Oligometastases From Breast Cancer Recruitment Status: Unknown status Trail description: Investigators designed a phase II study to evaluate safety and efficacy of lung and liver stereotactic radiation therapy (SRT) in oligometastatic breast cancer patients unsuitable for surgery, using VMAT RapidArc approach. Inclusion Criteria: Patients aged >18 years with ECOG 0-2
Diagnosis of Breast Cancer
DFI (Disease-free interval) > 1 year
No extrapulmonary and/or extrahepatic disease or other metastatic sites stable or responding after chemotherapy
No life threatening conditions
Lung and liver lesions < 5 (with maximum diameter < 5 cm)
Chemotherapy completed at least 3 weeks before treatment
Chemotherapy started at least 2 weeks after treatment allowed
Systemic therapies other than chemotherapy allowed (i.e hormonal therapies and/or immunotherapy)
Written informed consent Exclusion Criteria: ECOG > 2
Pregnant women
Patients with inability to consent </s> |
<s>[INST] Provide inclusion criteria for trial id: NCT02581670 [/INST] Patients aged >18 years with ECOG 0-2
Diagnosis of Breast Cancer
DFI (Disease-free interval) > 1 year
No extrapulmonary and/or extrahepatic disease or other metastatic sites stable or responding after chemotherapy
No life threatening conditions
Lung and liver lesions < 5 (with maximum diameter < 5 cm)
Chemotherapy completed at least 3 weeks before treatment
Chemotherapy started at least 2 weeks after treatment allowed
Systemic therapies other than chemotherapy allowed (i.e hormonal therapies and/or immunotherapy)
Written informed consent </s> |
<s>[INST] Provide exclusion criteria for trial id: NCT02581670 [/INST] ECOG > 2
Pregnant women
Patients with inability to consent </s> |
<s>[INST] Provide description for trial id: NCT02581670 [/INST] Investigators designed a phase II study to evaluate safety and efficacy of lung and liver stereotactic radiation therapy (SRT) in oligometastatic breast cancer patients unsuitable for surgery, using VMAT RapidArc approach. </s> |
<s>[INST] Provide title for trial id: NCT02581670 [/INST] Study on SBRT for Inoperable Lung and Liver Oligometastases From Breast Cancer </s> |
<s>[INST] Provide the recruitment status for trial id: NCT02581670 [/INST] Unknown status </s> |
<s>[INST] Provide the medical condition for trial id: NCT02581670 [/INST] Breast Cancer, Metastasis to Liver, Metastasis to Lung </s> |
<s>Trial Id: A Study to Determine the Clinical Significance of Molecular Detection of Breast Cancer in the Blood of Stage IV Breast Cancer Patients Recruitment Status: Completed Trail description: This study is designed to determine whether molecular detection of breast cancer cells in the peripheral blood of Stage IV breast cancer patients is a clinically relevant predictor of progression-free and overall survival. Stage IV breast cancer patients who have measurable breast cancer metastases and are initiating a regimen of systemic therapy are eligible for enrollment. Multi-marker real-time RT-PCR analysis will be performed on peripheral blood specimens from 92 breast cancer patients and 120 healthy volunteers. Peripheral blood specimens from breast cancer patients will be obtained at the time of study entry (prior to initiation of systemic therapy) and at serial time points during follow-up. Subjects will be followed longitudinally until death, although the study has been powered so that the primary objective can be addressed after 12 months of follow-up. Healthy volunteers will be asked to provide a blood sample at time of enrollment but will not be followed. Inclusion Criteria: Inclusion Criteria - Stage IV breast cancer patients
Patient age must be > 21 years.
Patient must have a tissue diagnosis of invasive breast cancer.
Patient must have documented evidence of metastatic disease.
Patient must have measurable lesions.
Patients must be initiating systemic therapy. Patients receiving hormonal therapy, and/or chemotherapy alone or in combination with other therapies are eligible.
Patient must have an ECOG performance status of 0, 1, or 2.
Patient must be available for follow-up.
Patient or their authorized legally acceptable representative must consent to be in the study and must have signed and dated an approved consent form which conforms to federal and institutional guidelines.
The patient with a previous history of non-breast malignancy is eligible for this study only if the patient meets the following criteria for a cancer survivor. A cancer survivor is eligible provided the following criteria are met: (1) patient has undergone potentially curative therapy for all prior malignancies, (2) patients have been considered disease free for at least 5 years (with the exception of basal cell or squamous cell carcinoma of the skin or carcinoma-in-situ of the cervix).
Inclusion Criteria - Healthy volunteers
A volunteer will be eligible for inclusion in this study only if ALL of the following criteria apply:
Volunteer age must be > 21 years.
Volunteer or their authorized legally acceptable representative must consent to be in the study and must have signed and dated an approved consent form which conforms to federal and institutional guidelines.
Patients with benign breast disease are eligible for enrollment.
The volunteer with a previous history of non-breast malignancy is eligible for this study only if the patient meets the following criteria for a cancer survivor. A cancer survivor is eligible provided both of the following criteria are met: (1) patient has undergone potentially curative therapy for all prior malignancies, (2) patient has been considered disease free for at least 5 years (with the exception of basal cell or squamous cell carcinoma of the skin or carcinoma-in-situ of the cervix). Exclusion Criteria: Exclusion Criteria - Stage IV breast cancer patients
A patient will be ineligible for inclusion in this study if ANY of the following criteria apply:
No documented metastatic disease.
No measurable lesions.
Bone only and/or brain metastasis.
Patient is not initiating a new regimen of systemic therapy. </s> |
<s>[INST] Provide inclusion criteria for trial id: NCT00355316 [/INST] Inclusion Criteria - Stage IV breast cancer patients
Patient age must be > 21 years.
Patient must have a tissue diagnosis of invasive breast cancer.
Patient must have documented evidence of metastatic disease.
Patient must have measurable lesions.
Patients must be initiating systemic therapy. Patients receiving hormonal therapy, and/or chemotherapy alone or in combination with other therapies are eligible.
Patient must have an ECOG performance status of 0, 1, or 2.
Patient must be available for follow-up.
Patient or their authorized legally acceptable representative must consent to be in the study and must have signed and dated an approved consent form which conforms to federal and institutional guidelines.
The patient with a previous history of non-breast malignancy is eligible for this study only if the patient meets the following criteria for a cancer survivor. A cancer survivor is eligible provided the following criteria are met: (1) patient has undergone potentially curative therapy for all prior malignancies, (2) patients have been considered disease free for at least 5 years (with the exception of basal cell or squamous cell carcinoma of the skin or carcinoma-in-situ of the cervix).
Inclusion Criteria - Healthy volunteers
A volunteer will be eligible for inclusion in this study only if ALL of the following criteria apply:
Volunteer age must be > 21 years.
Volunteer or their authorized legally acceptable representative must consent to be in the study and must have signed and dated an approved consent form which conforms to federal and institutional guidelines.
Patients with benign breast disease are eligible for enrollment.
The volunteer with a previous history of non-breast malignancy is eligible for this study only if the patient meets the following criteria for a cancer survivor. A cancer survivor is eligible provided both of the following criteria are met: (1) patient has undergone potentially curative therapy for all prior malignancies, (2) patient has been considered disease free for at least 5 years (with the exception of basal cell or squamous cell carcinoma of the skin or carcinoma-in-situ of the cervix). </s> |
<s>[INST] Provide exclusion criteria for trial id: NCT00355316 [/INST] Exclusion Criteria - Stage IV breast cancer patients
A patient will be ineligible for inclusion in this study if ANY of the following criteria apply:
No documented metastatic disease.
No measurable lesions.
Bone only and/or brain metastasis.
Patient is not initiating a new regimen of systemic therapy. </s> |
<s>[INST] Provide description for trial id: NCT00355316 [/INST] This study is designed to determine whether molecular detection of breast cancer cells in the peripheral blood of Stage IV breast cancer patients is a clinically relevant predictor of progression-free and overall survival. Stage IV breast cancer patients who have measurable breast cancer metastases and are initiating a regimen of systemic therapy are eligible for enrollment. Multi-marker real-time RT-PCR analysis will be performed on peripheral blood specimens from 92 breast cancer patients and 120 healthy volunteers. Peripheral blood specimens from breast cancer patients will be obtained at the time of study entry (prior to initiation of systemic therapy) and at serial time points during follow-up. Subjects will be followed longitudinally until death, although the study has been powered so that the primary objective can be addressed after 12 months of follow-up. Healthy volunteers will be asked to provide a blood sample at time of enrollment but will not be followed. </s> |
<s>[INST] Provide title for trial id: NCT00355316 [/INST] A Study to Determine the Clinical Significance of Molecular Detection of Breast Cancer in the Blood of Stage IV Breast Cancer Patients </s> |
<s>[INST] Provide the recruitment status for trial id: NCT00355316 [/INST] Completed </s> |
<s>[INST] Provide the medical condition for trial id: NCT00355316 [/INST] Breast Neoplasms </s> |
<s>Trial Id: Sodium (23Na) MRI for Tumour Characterisation and Assessment of Therapy Response in Breast Cancer Recruitment Status: Recruiting Trail description: The scope of this study is the methodological development and optimisation of sodium MRI (23Na-MRI) protocols for breast cancer imaging. The study further proposes to utilise biomarkers obtained from 23Na-imaging (cell integrity), FDG-PET (metabolism), multi-parametric MRI (perfusion, vascularity, cellularity, morphology) to generate parameter maps specific for physiological processes in breast cancer. Inclusion Criteria: None Exclusion Criteria: None </s> |
<s>[INST] Provide inclusion criteria for trial id: NCT03940092 [/INST] None </s> |
<s>[INST] Provide exclusion criteria for trial id: NCT03940092 [/INST] None </s> |
<s>[INST] Provide description for trial id: NCT03940092 [/INST] The scope of this study is the methodological development and optimisation of sodium MRI (23Na-MRI) protocols for breast cancer imaging. The study further proposes to utilise biomarkers obtained from 23Na-imaging (cell integrity), FDG-PET (metabolism), multi-parametric MRI (perfusion, vascularity, cellularity, morphology) to generate parameter maps specific for physiological processes in breast cancer. </s> |
<s>[INST] Provide title for trial id: NCT03940092 [/INST] Sodium (23Na) MRI for Tumour Characterisation and Assessment of Therapy Response in Breast Cancer </s> |
<s>[INST] Provide the recruitment status for trial id: NCT03940092 [/INST] Recruiting </s> |
<s>[INST] Provide the medical condition for trial id: NCT03940092 [/INST] Breast Cancer </s> |
<s>Trial Id: Triple Negative Breast Cancer: Study of Molecular and Genetic Factors Recruitment Status: Unknown status Trail description: Breast cancer triples negatives (TN; 15 % of the cases) are characterized by a high histoprognostic grade, a strong proliferation, a strong metastatic power, and a worse prognosis than the other forms of breast cancer. It is however a heterogenous group for histological and molecular level, but also for evolution. Most of the TN is part of the basal breast cancer subcategory. Until now, the medical treatment is based on chemotherapy.
Breast cancers by constitutional mutation of BRCA1 / BRCA2 (5 % of breast cancers) are mostly of basal type and their prognostic seems better that what could be expected from high grade tumours and without hormonal receptors. They would be much more frequent in the TN group. However, at this day, no prospective study was led to estimate this incidence, or to study the intervention of other genes of predisposition, as well to analyse the links between this phenotype and their consequences at the germinal or somatic level, in terms of associated molecular changes and prognosis.
The purpose of this study is, on a prospective study, to lead a joined analysis at the germinal level, in search of mutations of the main genes of breast cancer predisposition (BRCA1/2, PALB2, PTEN, PALB2), and at the tumour level (tissue micro-array and transcriptome), by correlating these results to the main clinical parameters.
The 5 years relapse-free survival will also be estimated. Inclusion Criteria: women > 18
non metastatic breast cancer
triple negative
5 years follow-up
signed informed consent Exclusion Criteria: other cancer (except in situ)
metastases at diagnosis
impossibility of follow-up </s> |
<s>[INST] Provide inclusion criteria for trial id: NCT01434420 [/INST] women > 18
non metastatic breast cancer
triple negative
5 years follow-up
signed informed consent </s> |
<s>[INST] Provide exclusion criteria for trial id: NCT01434420 [/INST] other cancer (except in situ)
metastases at diagnosis
impossibility of follow-up </s> |
<s>[INST] Provide description for trial id: NCT01434420 [/INST] Breast cancer triples negatives (TN; 15 % of the cases) are characterized by a high histoprognostic grade, a strong proliferation, a strong metastatic power, and a worse prognosis than the other forms of breast cancer. It is however a heterogenous group for histological and molecular level, but also for evolution. Most of the TN is part of the basal breast cancer subcategory. Until now, the medical treatment is based on chemotherapy.
Breast cancers by constitutional mutation of BRCA1 / BRCA2 (5 % of breast cancers) are mostly of basal type and their prognostic seems better that what could be expected from high grade tumours and without hormonal receptors. They would be much more frequent in the TN group. However, at this day, no prospective study was led to estimate this incidence, or to study the intervention of other genes of predisposition, as well to analyse the links between this phenotype and their consequences at the germinal or somatic level, in terms of associated molecular changes and prognosis.
The purpose of this study is, on a prospective study, to lead a joined analysis at the germinal level, in search of mutations of the main genes of breast cancer predisposition (BRCA1/2, PALB2, PTEN, PALB2), and at the tumour level (tissue micro-array and transcriptome), by correlating these results to the main clinical parameters.
The 5 years relapse-free survival will also be estimated. </s> |
<s>[INST] Provide title for trial id: NCT01434420 [/INST] Triple Negative Breast Cancer: Study of Molecular and Genetic Factors </s> |
<s>[INST] Provide the recruitment status for trial id: NCT01434420 [/INST] Unknown status </s> |
<s>[INST] Provide the medical condition for trial id: NCT01434420 [/INST] Breast Cancer </s> |
<s>Trial Id: Short and Long Term Effects of a Physical Therapy Program After Breast Cancer Surgery Recruitment Status: Suspended Trail description: Objectives: To evaluate the pressure pain threshold, shoulder biomechanics, cardiorespiratory function and the quality of life associated with the short and long-term physical therapy rehabilitation following breast cancer surgery. Methodology: The study presents three objectives and involves three groups of participants. Objective 1 is to develop a topographic map of pressure pain in the shoulder (using a digital pressure algometer), evaluate the biomechanics of the shoulder (using a digital inclinometer and load card), cardiorespiratory function (through frequency variability resting heart rate and distance traveled, through the six-minute walk test) and quality of life (through questionnaires of quality of life, anxiety, depression, sleep quality, upper limb functionality, fatigue and level of physical activity) between a group of women prior to the operation of breast cancer (experimental group, n = 36) and a group of asymptomatic controls for shoulder pain (control group, n = 18). Objective 2 is to evaluate the possible changes in the pain map over 24 weeks of supervised kinetic intervention (Supervised Physiotherapy experimental group, n = 18, will begin after drainage, frequency 3 times per week and duration of 60 minutes each session) compared to unsupervised kinetic intervention (Home Physiotherapy experimental group, n = 18, participants will receive an exercise booklet). Objective 3 is to evaluate the biomechanics of the shoulder, cardiorespiratory function and the quality of life with respect to the experimental group with and without kinesic supervision. To achieve objective 1, two baseline evaluations will be carried out in both experimental and control groups (considering the month prior to the surgery of the experimental group) and the average of the evaluations will be considered evaluation 1. To achieve objectives 2 and 3, evaluation 2 (after 4 weeks of intervention), 3 (after 12 weeks of intervention) and 4 (after 24 weeks of intervention) will be performed. The statistical analysis will include the examination of qualitative and quantitative variables. Statistical tests will be applied according to the normality of the data and a significance level of 5% will be adopted for all comparisons. Expected results: It is expected to identify sensory, biomechanical, cardiorespiratory and quality of life alterations in the experimental group, compared to the control group. In addition, after 24 weeks of intervention, the supervised experimental group will show improvement in all the aforementioned variables with respect to the unsupervised group. Inclusion Criteria: Surgical indication of conservative or removal breast surgery, associated with axillary lymphadenectomy or sentinel lymph node biopsy
Any type of breast cancer
Age range over 18 years Exclusion Criteria: Breast cancer recurrence;
Surgical treatment for bilateral breast cancer;
Presence of lymphedema in the upper limb, measured by means of cirtometry of the upper limb with a measuring tape 14, asymmetries of more than 1.5 cm between the limbs were considered edema;
Diagnosis of metastases;
Shoulder pain compatible with shoulder compression symptoms as determined by the positive Hawkins-Kennedy test 30;
Previous history of surgery and fractures in the upper extremities. </s> |
<s>[INST] Provide inclusion criteria for trial id: NCT04116281 [/INST] Surgical indication of conservative or removal breast surgery, associated with axillary lymphadenectomy or sentinel lymph node biopsy
Any type of breast cancer
Age range over 18 years </s> |
<s>[INST] Provide exclusion criteria for trial id: NCT04116281 [/INST] Breast cancer recurrence;
Surgical treatment for bilateral breast cancer;
Presence of lymphedema in the upper limb, measured by means of cirtometry of the upper limb with a measuring tape 14, asymmetries of more than 1.5 cm between the limbs were considered edema;
Diagnosis of metastases;
Shoulder pain compatible with shoulder compression symptoms as determined by the positive Hawkins-Kennedy test 30;
Previous history of surgery and fractures in the upper extremities. </s> |
<s>[INST] Provide description for trial id: NCT04116281 [/INST] Objectives: To evaluate the pressure pain threshold, shoulder biomechanics, cardiorespiratory function and the quality of life associated with the short and long-term physical therapy rehabilitation following breast cancer surgery. Methodology: The study presents three objectives and involves three groups of participants. Objective 1 is to develop a topographic map of pressure pain in the shoulder (using a digital pressure algometer), evaluate the biomechanics of the shoulder (using a digital inclinometer and load card), cardiorespiratory function (through frequency variability resting heart rate and distance traveled, through the six-minute walk test) and quality of life (through questionnaires of quality of life, anxiety, depression, sleep quality, upper limb functionality, fatigue and level of physical activity) between a group of women prior to the operation of breast cancer (experimental group, n = 36) and a group of asymptomatic controls for shoulder pain (control group, n = 18). Objective 2 is to evaluate the possible changes in the pain map over 24 weeks of supervised kinetic intervention (Supervised Physiotherapy experimental group, n = 18, will begin after drainage, frequency 3 times per week and duration of 60 minutes each session) compared to unsupervised kinetic intervention (Home Physiotherapy experimental group, n = 18, participants will receive an exercise booklet). Objective 3 is to evaluate the biomechanics of the shoulder, cardiorespiratory function and the quality of life with respect to the experimental group with and without kinesic supervision. To achieve objective 1, two baseline evaluations will be carried out in both experimental and control groups (considering the month prior to the surgery of the experimental group) and the average of the evaluations will be considered evaluation 1. To achieve objectives 2 and 3, evaluation 2 (after 4 weeks of intervention), 3 (after 12 weeks of intervention) and 4 (after 24 weeks of intervention) will be performed. The statistical analysis will include the examination of qualitative and quantitative variables. Statistical tests will be applied according to the normality of the data and a significance level of 5% will be adopted for all comparisons. Expected results: It is expected to identify sensory, biomechanical, cardiorespiratory and quality of life alterations in the experimental group, compared to the control group. In addition, after 24 weeks of intervention, the supervised experimental group will show improvement in all the aforementioned variables with respect to the unsupervised group. </s> |
<s>[INST] Provide title for trial id: NCT04116281 [/INST] Short and Long Term Effects of a Physical Therapy Program After Breast Cancer Surgery </s> |
<s>[INST] Provide the recruitment status for trial id: NCT04116281 [/INST] Suspended </s> |
<s>[INST] Provide the medical condition for trial id: NCT04116281 [/INST] Breast Cancer </s> |
<s>Trial Id: Prospective Breast Cancer Biobanking Recruitment Status: Enrolling by invitation Trail description: Prospective Breast Cancer Biobanking study (PBCB) will apply advanced monitoring in liquid biopsies of early staged breast cancer ration in order to facilitate A. Early detection of systemic relapses B.Improve adherence and drug monitoring av tamoxifen treatment C. Tumour microenvironment in breast cancer - adipose stromal immune infiltration and interaction with tumour at the growth zone D.Monitor side effects, QoL, depression, fatigue and work life participation Inclusion Criteria: Early stage Breast Cancer
DCIS gr III Exclusion Criteria: Not able to read Norwegian
Not able to communicate in Norwegian
Previously diagnosed with cancer
Dementia </s> |
<s>[INST] Provide inclusion criteria for trial id: NCT04488614 [/INST] Early stage Breast Cancer
DCIS gr III </s> |
<s>[INST] Provide exclusion criteria for trial id: NCT04488614 [/INST] Not able to read Norwegian
Not able to communicate in Norwegian
Previously diagnosed with cancer
Dementia </s> |
<s>[INST] Provide description for trial id: NCT04488614 [/INST] Prospective Breast Cancer Biobanking study (PBCB) will apply advanced monitoring in liquid biopsies of early staged breast cancer ration in order to facilitate A. Early detection of systemic relapses B.Improve adherence and drug monitoring av tamoxifen treatment C. Tumour microenvironment in breast cancer - adipose stromal immune infiltration and interaction with tumour at the growth zone D.Monitor side effects, QoL, depression, fatigue and work life participation </s> |
<s>[INST] Provide title for trial id: NCT04488614 [/INST] Prospective Breast Cancer Biobanking </s> |
<s>[INST] Provide the recruitment status for trial id: NCT04488614 [/INST] Enrolling by invitation </s> |
<s>[INST] Provide the medical condition for trial id: NCT04488614 [/INST] Breast Cancer </s> |
<s>Trial Id: The Study of Quadruple Therapy Quercetin, Zinc, Metformin, and EGCG as Adjuvant Therapy for Early, Metastatic Breast Cancer and Triple-negative Breast Cancer, a Novel Mechanism Recruitment Status: Not yet recruiting Trail description: breast cancer is the most common cancer in women. With more than 1 in 10 new cancer diagnoses each year, It is the second most frequent cancer-related death among women worldwide. Breast cancer develops slowly, and the majority of cases are found through routine screening.
breast cancer-causing deaths among women all over the world and increased in the last few years even though the treatment is advanced like immunotherapy chemotherapy by yet no treatment for triple-negative breast cancer zinc and competition between znt1 and zip6,10 at breast cancer cells. Is zinc ionophore like quercetin and EGCG has a role, In a novel experimental study zinc is a trace metal that has many roles in cells, enzymatic activity, and gene regulations, and also for the integrity of DNA.
Zinc transporters (zinc related -proteins such as ZIPs, and ZnTs are affected by triggers factors like cytokines and growth factors.
There are two large families of zinc transporters like ZIPs ( 14 members) and ZnTs family (10 members), ZIPS family cause an influx of zinc from the extracellular to the cytoplasm and also from intracellular organelles like endoplasmic reticulum or Golgi or mitochondria in contrast to ZnTs which cause an influx of zinc from the cytoplasm to intracellular organelles. ( lower cytoplasmic zinc) (1) Breast cancer deaths occurred from metastasis; Catalytic enzymes called proteases like cathepsin L are frequently overexpressed in aggressive cancers. Breast tumor metastatic potential is correlated with macrophage presence. These macrophages associated with tumors frequently adopt an M2-like pro-tumorigenic phenotype, which results in the production of growth hormones and proteases, notably the lysosomal protease cathepsin L. Because cathepsin L is commonly released by breast cancer cells and aids in tumor invasion, metastasis, and angiogenesis. It is expected that cathepsin L secretion by both tumor-associated macrophages and neoplastic cells would promote the metastatic phenotype because cathepsin L is widely produced by breast cancer cells and helps with tumor invasion, metastasis, and angiogenesis. (2) this study target new mechanisms and achieves the best management as some types of cancer breast like triple-negative breast cancer (TNBC) no definite treatment so we target the following pathways and epigenetic processes by these adjuvant compounds which have a promising role in the immunity like EGCG, Quercetin, Zinc, Metformin so our team will discuss novel methods to achieve the best efficacy from chemotherapy Inclusion Criteria: Age above 18
Female patients
with any type of breast cancer Ductal carcinoma in situ (DCIS) ... Invasive breast cancer (ILC or IDC) ... Triple-negative breast cancer. ... Inflammatory breast cancer. ... Paget disease of the breast. ... Angiosarcoma. ... Phyllodes tumor.
HER2-positive by ASCO CAP 2018 guidelines, confirmed by central testing
Participants must have normal organ and marrow function as defined below:
ANC ≥ 1000/mm3 hemoglobin ≥8 g/dl platelets ≥ 75,000/mm3 AST and ALT both <5x institutional ULN Total bilirubin ≤ 1.5 mg/dL. For patients with Gilbert syndrome, the direct bilirubin should be <institutional ULN Serum creatinine ≤ 2.0 mg/dL OR calculated GFR ≥ 30mL/min 6- Locally advanced tumors at diagnosis, including tumors fixed to the chest wall, peau d'orange, skin ulcerations/nodules, or clinical inflammatory changes (diffuse brawny cutaneous induration with an erysipeloid edge) Patients with a history of previous invasive breast cancer.
- Exclusion Criteria: Neoadjuvant or adjuvant chemotherapy for this breast cancer prior to enrollment is prohibited.
Any of the following due to teratogenic potential of the study drugs:
Pregnant women Nursing women Women of childbearing potential who are unwilling to employ adequate contraception (condoms, diaphragms, IUDS, surgical sterilization, abstinence, etc). Hormonal birth control methods are not permitted.
Participants who are receiving any other investigational agents for treatment of breast cancer, unless specific approval is obtained from the Sponsor-Investigator.
- </s> |
<s>[INST] Provide inclusion criteria for trial id: NCT05680662 [/INST] Age above 18
Female patients
with any type of breast cancer Ductal carcinoma in situ (DCIS) ... Invasive breast cancer (ILC or IDC) ... Triple-negative breast cancer. ... Inflammatory breast cancer. ... Paget disease of the breast. ... Angiosarcoma. ... Phyllodes tumor.
HER2-positive by ASCO CAP 2018 guidelines, confirmed by central testing
Participants must have normal organ and marrow function as defined below:
ANC ≥ 1000/mm3 hemoglobin ≥8 g/dl platelets ≥ 75,000/mm3 AST and ALT both <5x institutional ULN Total bilirubin ≤ 1.5 mg/dL. For patients with Gilbert syndrome, the direct bilirubin should be <institutional ULN Serum creatinine ≤ 2.0 mg/dL OR calculated GFR ≥ 30mL/min 6- Locally advanced tumors at diagnosis, including tumors fixed to the chest wall, peau d'orange, skin ulcerations/nodules, or clinical inflammatory changes (diffuse brawny cutaneous induration with an erysipeloid edge) Patients with a history of previous invasive breast cancer.
- </s> |
<s>[INST] Provide exclusion criteria for trial id: NCT05680662 [/INST] Neoadjuvant or adjuvant chemotherapy for this breast cancer prior to enrollment is prohibited.
Any of the following due to teratogenic potential of the study drugs:
Pregnant women Nursing women Women of childbearing potential who are unwilling to employ adequate contraception (condoms, diaphragms, IUDS, surgical sterilization, abstinence, etc). Hormonal birth control methods are not permitted.
Participants who are receiving any other investigational agents for treatment of breast cancer, unless specific approval is obtained from the Sponsor-Investigator.
- </s> |
<s>[INST] Provide description for trial id: NCT05680662 [/INST] breast cancer is the most common cancer in women. With more than 1 in 10 new cancer diagnoses each year, It is the second most frequent cancer-related death among women worldwide. Breast cancer develops slowly, and the majority of cases are found through routine screening.
breast cancer-causing deaths among women all over the world and increased in the last few years even though the treatment is advanced like immunotherapy chemotherapy by yet no treatment for triple-negative breast cancer zinc and competition between znt1 and zip6,10 at breast cancer cells. Is zinc ionophore like quercetin and EGCG has a role, In a novel experimental study zinc is a trace metal that has many roles in cells, enzymatic activity, and gene regulations, and also for the integrity of DNA.
Zinc transporters (zinc related -proteins such as ZIPs, and ZnTs are affected by triggers factors like cytokines and growth factors.
There are two large families of zinc transporters like ZIPs ( 14 members) and ZnTs family (10 members), ZIPS family cause an influx of zinc from the extracellular to the cytoplasm and also from intracellular organelles like endoplasmic reticulum or Golgi or mitochondria in contrast to ZnTs which cause an influx of zinc from the cytoplasm to intracellular organelles. ( lower cytoplasmic zinc) (1) Breast cancer deaths occurred from metastasis; Catalytic enzymes called proteases like cathepsin L are frequently overexpressed in aggressive cancers. Breast tumor metastatic potential is correlated with macrophage presence. These macrophages associated with tumors frequently adopt an M2-like pro-tumorigenic phenotype, which results in the production of growth hormones and proteases, notably the lysosomal protease cathepsin L. Because cathepsin L is commonly released by breast cancer cells and aids in tumor invasion, metastasis, and angiogenesis. It is expected that cathepsin L secretion by both tumor-associated macrophages and neoplastic cells would promote the metastatic phenotype because cathepsin L is widely produced by breast cancer cells and helps with tumor invasion, metastasis, and angiogenesis. (2) this study target new mechanisms and achieves the best management as some types of cancer breast like triple-negative breast cancer (TNBC) no definite treatment so we target the following pathways and epigenetic processes by these adjuvant compounds which have a promising role in the immunity like EGCG, Quercetin, Zinc, Metformin so our team will discuss novel methods to achieve the best efficacy from chemotherapy </s> |
<s>[INST] Provide title for trial id: NCT05680662 [/INST] The Study of Quadruple Therapy Quercetin, Zinc, Metformin, and EGCG as Adjuvant Therapy for Early, Metastatic Breast Cancer and Triple-negative Breast Cancer, a Novel Mechanism </s> |
<s>[INST] Provide the recruitment status for trial id: NCT05680662 [/INST] Not yet recruiting </s> |
<s>[INST] Provide the medical condition for trial id: NCT05680662 [/INST] Breast Cancer Female, Triple Negative Breast Cancer </s> |
<s>Trial Id: Evaluation the Diagnostic Ability of the Cancer Detection Technology (CDT) to Detect Breast Cancer Among Women Population Over Age 40 Recruitment Status: Unknown status Trail description: This study aimed to validate the diagnostic ability of the CDT (cancer detection technology) software to detect breast cancer among women population. Inclusion Criteria: Inclusion Criteria for Breast Cancer Patients for Experimental Group:
Patient is over the age of 40.
Patient is willing to participate as evidenced by signing the written informed consent form.
Patient referred to the Department of Oncology/ Surgery for operative treatment of breast cancer with previously detected disease. Positive conventional tests finding can include (but not limited to) the record of screening or diagnostic mammography, blood oncomarkers, breast ultrasound, breast CT, biopsy.
Non-treated patients (w/o previous chemotherapy, hormonal drugs and radiotherapy).
Patient without other cancer locations
Inclusion Criteria for Presumably Healthy Subjects for Control Group:
Subjects over the age of 40.
Subjects who are willing to participate as evidenced by signing the written informed consent form.
Subjects who are presumably healthy and without breast pathologies' symptoms and family history of breast cancer, i.e., breast disease (except history of functional breast problems, e.g., mastitis within lactation period) has been ruled out based on physician anamnesis
Subjects with negative results of screening mammography.
Subjects without taking of any hormonal medicines Exclusion Criteria: Subjects with any known cancer in other internal organs or systems.
Subjects with high fever presentation (more than 38.5).
Subjects with known breast disease undergoing treatment for the disease.
Pregnant or lactating women </s> |
<s>[INST] Provide inclusion criteria for trial id: NCT01043055 [/INST] Inclusion Criteria for Breast Cancer Patients for Experimental Group:
Patient is over the age of 40.
Patient is willing to participate as evidenced by signing the written informed consent form.
Patient referred to the Department of Oncology/ Surgery for operative treatment of breast cancer with previously detected disease. Positive conventional tests finding can include (but not limited to) the record of screening or diagnostic mammography, blood oncomarkers, breast ultrasound, breast CT, biopsy.
Non-treated patients (w/o previous chemotherapy, hormonal drugs and radiotherapy).
Patient without other cancer locations
Inclusion Criteria for Presumably Healthy Subjects for Control Group:
Subjects over the age of 40.
Subjects who are willing to participate as evidenced by signing the written informed consent form.
Subjects who are presumably healthy and without breast pathologies' symptoms and family history of breast cancer, i.e., breast disease (except history of functional breast problems, e.g., mastitis within lactation period) has been ruled out based on physician anamnesis
Subjects with negative results of screening mammography.
Subjects without taking of any hormonal medicines </s> |
<s>[INST] Provide exclusion criteria for trial id: NCT01043055 [/INST] Subjects with any known cancer in other internal organs or systems.
Subjects with high fever presentation (more than 38.5).
Subjects with known breast disease undergoing treatment for the disease.
Pregnant or lactating women </s> |
<s>[INST] Provide description for trial id: NCT01043055 [/INST] This study aimed to validate the diagnostic ability of the CDT (cancer detection technology) software to detect breast cancer among women population. </s> |
<s>[INST] Provide title for trial id: NCT01043055 [/INST] Evaluation the Diagnostic Ability of the Cancer Detection Technology (CDT) to Detect Breast Cancer Among Women Population Over Age 40 </s> |
<s>[INST] Provide the recruitment status for trial id: NCT01043055 [/INST] Unknown status </s> |
<s>[INST] Provide the medical condition for trial id: NCT01043055 [/INST] Breast Cancer </s> |
<s>Trial Id: Oncoliq: Test for Early Breast Cancer Detection. Recruitment Status: Recruiting Trail description: Oncoliq is a novel early breast cancer detection test based on liquid biopsies and microRNAs. This innovative test will allow improving the accuracy of cancer detection which will impact on health, reducing the patient mortality and health costs.
To develop this test, it has been finished the preclinical PHASE I: in laboratory animals; PHASE II: exploratory clinical phase for the discovery of candidate biomarkers in breast cancer patients and PHASE III: clinical validation of biomarkers showing that Oncoliq has 91% of sensitivity.
Currently it is been setting up a "pilot test" for breast cancer to enrol 500 woman volunteers without previous cancer diagnosis that go to the annual medical control. The results of the pilot test will give the accuracy for early breast cancer detection. Inclusion Criteria: Women patients performing gynecological control
Between 50-70 years old
Without personal history of oncological disease
Informed consent signed Exclusion Criteria: Patients who don´t meet the inclusion criteria.
Active infection with SARS-CoV-2 (COVID-19). </s> |
<s>[INST] Provide inclusion criteria for trial id: NCT04906330 [/INST] Women patients performing gynecological control
Between 50-70 years old
Without personal history of oncological disease
Informed consent signed </s> |
<s>[INST] Provide exclusion criteria for trial id: NCT04906330 [/INST] Patients who don´t meet the inclusion criteria.
Active infection with SARS-CoV-2 (COVID-19). </s> |
<s>[INST] Provide description for trial id: NCT04906330 [/INST] Oncoliq is a novel early breast cancer detection test based on liquid biopsies and microRNAs. This innovative test will allow improving the accuracy of cancer detection which will impact on health, reducing the patient mortality and health costs.
To develop this test, it has been finished the preclinical PHASE I: in laboratory animals; PHASE II: exploratory clinical phase for the discovery of candidate biomarkers in breast cancer patients and PHASE III: clinical validation of biomarkers showing that Oncoliq has 91% of sensitivity.
Currently it is been setting up a "pilot test" for breast cancer to enrol 500 woman volunteers without previous cancer diagnosis that go to the annual medical control. The results of the pilot test will give the accuracy for early breast cancer detection. </s> |
<s>[INST] Provide title for trial id: NCT04906330 [/INST] Oncoliq: Test for Early Breast Cancer Detection. </s> |